Effects of an oral contraceptive combination containing 0.150 mg desogestrel plus 0.020 mg ethinyl estradiol on healthy premenopausal women. 1993

D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
Department of Obstetrics and Gynecology, University of Bologna, Italy.

Twenty-six healthy premenopausal outpatients from the Menopause Clinic of the University of Bologna were treated with a combination pill containing 0.020 mg of ethinyl estradiol and 0.150 mg of desogestrel for one year. Throughout the treatment period, clinical and laboratory monitoring was periodically performed, and women were asked about the occurrence of climacteric symptoms. This formulation relieved climacteric symptoms, and did not adversely affect lipids and clotting factors, except for a slight increase in serum triglycerides. Laboratory data also suggest a beneficial effect on bone metabolism.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D002979 Climacteric Physiologic period, characterized by endocrine, somatic, and psychic changes with the termination of ovarian function in the female. It may also accompany the normal diminution of sexual activity in the male. Change of Life,Climacterics,Life Change,Life Changes
D003277 Contraceptives, Oral, Combined Fixed drug combinations administered orally for contraceptive purposes. Combined Oral Contraceptive,Contraceptive Agents, Female, Combined,Oral Contraceptives, Combined,Combined Oral Contraceptives,Contraceptive, Combined Oral,Contraceptives, Combined Oral,Oral Contraceptive, Combined
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral

Related Publications

D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
January 1982, Clinical therapeutics,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
January 1987, Acta obstetricia et gynecologica Scandinavica. Supplement,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
December 1996, Contraception,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
June 1989, Arzneimittel-Forschung,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
April 1994, Fertility and sterility,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
January 1992, International journal of fertility,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
January 1993, International journal of fertility and menopausal studies,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
January 1988, Acta obstetricia et gynecologica Scandinavica,
D de Aloysio, and M Mauloni, and A Roncuzzi, and P Altieri, and F Bottiglioni, and G F Trossarelli, and G Fanizza, and A Covelli
January 2014, Acta medica Iranica,
Copied contents to your clipboard!